TKT and neoplasm: In addition to the option of using anti- EGFR therapies in combination with anti-VEGF drugs, a series of tyrosine kinases that block both the EGFR and the VEGF receptor TK were developed, such as vandetanib, which has demonstrated significant activity as single agent and in combination with traditional chemotherapeutics in several human tumor types [27]–[29].